Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pulsatilla 30C is a homeopathic remedy derived from the *Pulsatilla nigricans* (pasqueflower) plant, prepared through a process of serial dilution and succussion to a 30C potency. It is being evaluated by the Shaare Zedek Medical Center in Jerusalem, Israel, for the treatment of premenstrual syndrome (PMS). In the clinical trial NCT02402049, it is utilized as part of an individualized homeopathic approach where the specific remedy is selected based on the patient's unique physical and emotional symptom profile. As a homeopathic preparation at a 30C dilution, it does not contain detectable levels of the original plant material and lacks a conventional pharmacological mechanism of action or defined molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pulsatilla 30C.